{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"description":"Best overall response rate as assessed by the investigator by RECIST v1.1 (or by RECIST v1.1 and PCWG3 in participants with advanced prostate cancer).","groups":[{"description":"Participants with a deleterious mutation in one of the following genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.","id":"OG000","title":"Rucaparib Cohort A"},{"description":"Participants with a deleterious mutation in one of the following genes: BARD1, BRIP1, FANCA, NBN, RAD51, or RAD51B.","id":"OG001","title":"Rucaparib Cohort B"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Efficacy population - all participants evaluable for response by RECIST v1.1 (or modified RECIST v1.1/PCWG3 for mCRPC participants).","reportingStatus":"POSTED","timeFrame":"From first dose of study drug until disease progression (up to approximately 2 years)","title":"Best Overall Response Rate by Investigator","type":"PRIMARY","unitOfMeasure":"Participants"}